In an effort to understand the heterogeneity observed in clinical trials of GLP-1 RAs, we conducted a meta-analysis of aggregate data from CVOTs and applied meta-regression methods to more comprehensively understand the cardiovascular benefits of GLP-1 RAs in patients with T2D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.